1.A Survey of the Collection, Provision, and Application of Drug Safety Information at Hospitals
Maki Masuyama ; Hirokazu Hasegawa ; Mie Ikeda ; Kazuhiko Mori ; Keiko Yoshino ; Yoshiaki Ara ; Hisanori Miyashita ; Yasuo Ide ; Yoshihiko Suzuki ; Masahiro Hayashi ; Tsutomu Matsuda
Japanese Journal of Drug Informatics 2013;14(4):170-178
Objective: We conducted a questionnaire survey to comprehend the situation regarding the collection, provision, and utilization of drug safety information at hospitals. In addition, we asked pharmaceutical companies how they select medical institutions to provide drug safety information. We also investigated the current situation of information provision to Tokyo Medial Center by pharmaceutical companies.
Method: A questionnaire was mailed to all hospitals in Japan. The survey was conducted between January 13 and February 10, 2011. Moreover, we asked thirteen pharmaceutical companies by telephone and e-mail about the implementation status of the provision of information and performed a survey at Tokyo Medical Center on the current situation of information provision by pharmaceutical companies regarding revisions to precaution sections in package inserts.
Results: The results of the questionnaire survey (response rate: 41.2%) showed that the major information sources for hospitals were medical representatives (77.8%), Drug Safety Update (50.3%) and direct mails (49.3%). Furthermore, in the case of drugs prescribed exclusively for extramural dispensing, fewer hospitals responded that medical representatives of the pharmaceutical companies provided drug safety information and more hospitals responded that they did not obtain any drug safety information at all, compared with drugs listed in the hospital formularies.
Conclusion: To minimize the risks of drugs, healthcare professionals must collect a wide range of drug safety information and must utilize this information in their medical practice. Therefore, it is important that pharmaceutical companies and regulatory authorities make an effort to provide suitable information dissemination to medical institutions. Furthermore, medical institutions must also strengthen their systems for collecting drug safety information and providing such information to healthcare professionals.
2.Hokkaido birth cohort study on environment and children's health: cohort profile 2021.
Reiko KISHI ; Atsuko IKEDA-ARAKI ; Chihiro MIYASHITA ; Sachiko ITOH ; Sumitaka KOBAYASHI ; Yu AIT BAMAI ; Keiko YAMAZAKI ; Naomi TAMURA ; Machiko MINATOYA ; Rahel Mesfin KETEMA ; Kritika POUDEL ; Ryu MIURA ; Hideyuki MASUDA ; Mariko ITOH ; Takeshi YAMAGUCHI ; Hisanori FUKUNAGA ; Kumiko ITO ; Houman GOUDARZI
Environmental Health and Preventive Medicine 2021;26(1):59-59
BACKGROUND:
The Hokkaido Study on Environment and Children's Health is an ongoing study consisting of two birth cohorts of different population sizes: the Sapporo cohort and the Hokkaido cohort. Our primary objectives are to (1) examine the effects that low-level environmental chemical exposures have on birth outcomes, including birth defects and growth retardation; (2) follow the development of allergies, infectious diseases, and neurobehavioral developmental disorders, as well as perform a longitudinal observation of child development; (3) identify high-risk groups based on genetic susceptibility to environmental chemicals; and (4) identify the additive effects of various chemicals, including tobacco.
METHODS:
The purpose of this report is to provide an update on the progress of the Hokkaido Study, summarize recent results, and suggest future directions. In particular, this report provides the latest details from questionnaire surveys, face-to-face examinations, and a collection of biological specimens from children and measurements of their chemical exposures.
RESULTS:
The latest findings indicate different risk factors of parental characteristics on birth outcomes and the mediating effect between socioeconomic status and children that are small for the gestational age. Maternal serum folate was not associated with birth defects. Prenatal chemical exposure and smoking were associated with birth size and growth, as well as cord blood biomarkers, such as adiponectin, leptin, thyroid, and reproductive hormones. We also found significant associations between the chemical levels and neuro development, asthma, and allergies.
CONCLUSIONS
Chemical exposure to children can occur both before and after birth. Longer follow-up for children is crucial in birth cohort studies to reinforce the Developmental Origins of Health and Disease hypothesis. In contrast, considering shifts in the exposure levels due to regulation is also essential, which may also change the association to health outcomes. This study found that individual susceptibility to adverse health effects depends on the genotype. Epigenome modification of DNA methylation was also discovered, indicating the necessity of examining molecular biology perspectives. International collaborations can add a new dimension to the current knowledge and provide novel discoveries in the future.
Biomarkers/blood*
;
Child
;
Child Health
;
Child, Preschool
;
Cohort Studies
;
Environmental Exposure/adverse effects*
;
Environmental Health
;
Environmental Pollutants/adverse effects*
;
Female
;
Fetal Blood/chemistry*
;
Follow-Up Studies
;
Growth/drug effects*
;
Humans
;
Hypersensitivity/etiology*
;
Infant
;
Japan/epidemiology*
;
Male
;
Neurodevelopmental Disorders/etiology*
;
Pregnancy
;
Prenatal Exposure Delayed Effects/etiology*
;
Prevalence
;
Smoking/adverse effects*